The results, published in the Journal of Clinical Pharmacology, support the nalmefene auto-injector as an important treatment option to support emergency opioid overdose reversal STAMFORD, Conn., Sept. 29, 2025 – A pharmacodynamic study sponsored by Purdue Pharma...
Stamford, Conn., Sept. 17, 2025 – Purdue Pharma L.P. (“Purdue”) has entered into an agreement to have its pipeline medication tinostamustine included in the Phase 2/3 GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) adaptive clinical trial for...
Data demonstrate positive preliminary results for investigational agent sunobinop as a potential first-in-class treatment for interstitial cystitis/bladder pain syndrome Stamford, CT- September 9, 2025 - Purdue Pharma L.P. (“Purdue”), announced positive...
STAMFORD, Conn., Sept. 2, 2025 – Purdue Pharma L.P. (“Purdue”) announced today, in recognition of International Overdose Awareness Day, that the Company has expanded its partnership with MMCAP to provide buprenorphine and naloxone tablets CIII (generic Suboxone®), a...
Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.